SWP
TCRX icon

Strategic Wealth Partners’s TScan Therapeutics TCRX Stock Holding History

Strategic Wealth Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305 Hold
311
– – ﹤0.01% 1355
2026
Q1 		$314 Hold
311
– – ﹤0.01% 1351
2025
Q4 		$311 Hold
311
– – ﹤0.01% 1367
2025
Q3 		$566 Hold
311
– – ﹤0.01% 1250
2025
Q2 		$451 Buy
+311
New +$449 ﹤0.01% 1084

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Strategic Wealth Partners's TCRX Position: Q2 2026 in Review

Strategic Wealth Partners held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 311 shares worth $305. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Strategic Wealth Partners first reported a position in TCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $566 in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Strategic Wealth Partners held 311 shares of TScan Therapeutics worth $305 as of Q2 2026.
  • Strategic Wealth Partners left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q2 2026, its #1355 holding.
  • Strategic Wealth Partners first reported a position in TScan Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Strategic Wealth Partners's TScan Therapeutics position peaked at $566 in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.